Sugarcane supplement and exercise may team up to tame cholesterol

NCT ID NCT07710261

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This study tests whether a low-dose sugarcane-derived supplement called policosanol, combined with a structured exercise program, can improve physical fitness and blood lipid levels in adults with elevated cholesterol who do not yet need medication. Over 12 weeks, participants are randomly assigned to receive policosanol or a placebo, with or without exercise training. The goal is to see if this combination offers a natural way to support heart health and fitness.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
policosanol (a dietary supplement derived from sugarcane, also known as octacosanol)
What this could lead to
If it works, this could point toward a simple, low-cost way to improve cholesterol and physical fitness in people with mildly elevated blood lipids who do not yet need medication.
What could go wrong
This is a small, early-stage trial with only 120 participants, and the dose of policosanol is low. The results may not be strong enough to recommend it widely, and supplements are not as strictly regulated as drugs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 to 59 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men and women aged 25 to 59 years. * BMI between 18.5 and 29.9 kg/m². * Diagnosed with or presenting with dyslipidemia within the past 3 months, based on laboratory assessment at baseline or a standard laboratory report issued within the past 3 months, according to the National Cholesterol Education Program Adult Treatment Panel III criteria, defined by at least one of the following: * Total cholesterol ≥ 200 mg/dL; * Low-density lipoprotein cholesterol ≥ 130 mg/dL and \< 190 mg/dL; * High-density lipoprotein cholesterol \< 40 mg/dL in men; * High-density lipoprotein cholesterol \< 50 mg/dL in women; * Triglycerides ≥ 150 mg/dL. * Free from chronic or comorbid conditions that contraindicate participation in aerobic or resistance exercise. * Cleared for physical activity based on the Physical Activity Readiness Questionnaire for Everyone. * Not regularly physically active during the preceding 3 months, defined as fewer than 3 exercise sessions per week or less than 150 minutes of exercise per week. * Able and willing to participate in the study procedures and provide written informed consent. Exclusion Criteria: * Current or recent use within the past 3 months of lipid-lowering medications or dietary supplements known to influence lipid metabolism, including statins, fibrates, niacin, omega-3 fatty acids, red yeast rice, or policosanol. * Known allergy or hypersensitivity to policosanol, sugarcane derivatives, capsule components, or any excipients in the supplement formulation. * Presence of chronic or comorbid conditions that may make exercise participation unsafe, including but not limited to cardiovascular disease, chronic obstructive pulmonary disease, severe arthritis, osteoporosis, uncontrolled diabetes, gastrointestinal disorders, or neurological impairments affecting movement control. * High-risk lifestyle factors, including heavy smoking, excessive alcohol consumption, or use of recreational drugs. Inability to comply with the study protocol, including inability to participate in the exercise program when assigned or inability to attend scheduled follow-up assessments. \- Refusal or inability to provide written informed consent independently.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dyslipidemia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Institute of Nutrition, Mahidol University

    Nakhon Pathom, 73170, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.